Marshall Wace’s Protalix BioTherapeutics PLX Stock Holding History

Marshall Wace’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.05M	Buy	+452,757	New	+$959K	﹤0.01%	2164
2026 Q1	–	Sell	-19,079	Closed	-$34.3K	–	3580
2025 Q4	$34.3K	Buy	+19,079	New	+$39K	﹤0.01%	2802
2025 Q2	–	Sell	-615,085	Closed	-$1.57M	–	3055
2025 Q1	$1.57M	Buy	615,085 +513,186	+504%	+$1.23M	﹤0.01%	1574
2024 Q4	$192K	Buy	+101,899	New	+$144K	﹤0.01%	2364
2023 Q3	–	Sell	-562,139	Closed	-$1.12M	–	2565
2023 Q2	$1.12M	Buy	562,139 +411,781	+274%	+$981K	﹤0.01%	1663
2023 Q1	$316K	Buy	+150,358	New	+$264K	﹤0.01%	2281

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Marshall Wace's PLX Position: Q2 2026 in Review

Marshall Wace opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 452,757 shares worth $1.05M. The stake represents ﹤0.01% of the portfolio and ranks #2164 among its holdings. This is a return to the name: Marshall Wace previously reported a position in PLX as recently as Q4 2025.

Marshall Wace first reported a position in PLX in Q1 2023 and has held it in 6 quarters since. The position peaked at $1.57M in Q1 2025. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Marshall Wace held 452,757 shares of Protalix BioTherapeutics worth $1.05M as of Q2 2026.
Protalix BioTherapeutics was a new Marshall Wace position in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2164 holding.
Marshall Wace first reported a position in Protalix BioTherapeutics in Q1 2023 and has held it in 6 quarters since.
Marshall Wace's Protalix BioTherapeutics position peaked at $1.57M in Q1 2025.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.